Lloyd Williams
Cornea and External Diseases Specialist · Durham, NCNPI 1730333741
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,100 of the $7,008 with a category attached, or 72.8%. Johnson & Johnson Surgical Vision, Inc. accounts for 80.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $3,216 and has fallen 95.6% since, to $143 in 2025.
Across 29 payments — averaging $241.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$6K
- Kala Pharmaceuticals, Inc.$405
- Alcon$293
- Novartis$251
- Alcon Research LLC$150
- Carl Zeiss Meditec USA, Inc.$149
- plus $151 from 3 others
What the payments were for
- Consulting fees$5,10073%
- Food & beverage$1,90827%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 9 | $5,610 |
| Kala Pharmaceuticals, Inc. | 4 | $405 |
| Alcon | 4 | $293 |
| Novartis | 3 | $251 |
| Alcon Research LLC | 2 | $150 |
| Carl Zeiss Meditec USA, Inc. | 1 | $149 |
| Sight Sciences, Inc. | 4 | $72 |
| Rxsight Inc | 1 | $60 |
| Ocular Therapeutix, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTRALASE FS FEMTOSEC LASER$2,700
- INVELTYS$396
- EYSUVIS$396
- XIIDRA$223
- Tecnis IOL$217
- IDESIGN RS$136
- AcrySof UltraSert$122
- Clareon$110
How this compares
Too few cornea and external diseases specialist providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 13 | $10,053 |
| Prednisolone Acetate | 178 | $7,133 |
| Loteprednol Etabonate | 11 | $1,889 |
| MoxifloxacinMoxifloxacin Hcl | 41 | $929 |
| Ketorolac Tromethamine | 34 | $814 |
| Ofloxacin | 63 | $638 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $501 |
| Brimonidine Tartrate | 34 | $198 |
| ErythromycinErythromycin Base | 12 | $168 |
| Latanoprost | 15 | $84 |
Paid to pharmacies, not to this prescriber.
Other cornea and external diseases specialist in Durham
- Victor Perez QuinonesDurham$179K
- Yun Bo TianDurham$4K
- Michelle KimDurham$424
- Adam BennettRaleigh$5K
- Sara SpyrisWinston Salem$2K
- Brent HoffmanRaleigh$2K
- Anthony TangWilmington$1K
- Patricia SmithRaleigh$323
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.